[Treatment of Guillain-Barré Syndrome].

Szczegóły
Abstrakt

Tytuł:: [Treatment of Guillain-Barré Syndrome].
Autorzy:: Nomura K; Department of Neurology, Saitama Medical Center.
Źródło:: Brain and nerve = Shinkei kenkyu no shinpo [Brain Nerve] 2015 Nov; Vol. 67 (11), pp. 1397-410.
Typ publikacji:: English Abstract; Journal Article; Review
Język:: Japanese
Imprint Name(s):: Original Publication: Tōkyō : igaku Shoin
MeSH Terms:: Plasma Exchange*
Practice Guidelines as Topic*
Adrenal Cortex Hormones/*therapeutic use
Guillain-Barre Syndrome/*therapy
Immunoglobulins, Intravenous/*therapeutic use
Animals ; Guillain-Barre Syndrome/diagnosis ; Humans ; Immunoglobulins, Intravenous/administration & dosage ; Treatment Outcome
Substance Nomenclature:: 0 (Adrenal Cortex Hormones)
0 (Immunoglobulins, Intravenous)
Entry Date(s):: Date Created: 20151113 Date Completed: 20160222 Latest Revision: 20151112
Update Code:: 20240104
DOI:: 10.11477/mf.1416200312
PMID:: 26560955
: Czasopismo naukowe

The treatment of Guillain-Barre syndromé (GBS) was mainly symptomatic until the 1950s, followed by corticosteroid treatment in the 1950s through 1960s. Plasma exchange (PE) was then performed during 1970s through the 1980s, after which intravenous immunoglobulin (IVIg) was performed in 1990s through the 2000s. The effectiveness of IVIg and PE has been established by randomized controlled trial(RCT). Recently, new treatments using biological products have been explored. In this paper, we summarize the development of the treatment of GBS.

Informacja